Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin

Blood

Volumn 88, Issue 7, 1996, Pages 2465-2472

  Preas II, Hugh L ^a   Reda, Debra ^b   Tropea, Margaret ^b   Vandivier, R William ^b   Banks, Steven M ^b   Agosti, Jan M ^b   Suffredini, Anthony F ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 1 RECEPTOR;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; INFLAMMATORY CELL; LEUKOCYTOSIS; MALE; MEDIATOR RELEASE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE;

ACUTE-PHASE REACTION; ADULT; BIOLOGICAL RESPONSE MODIFIERS; BLOOD CELL COUNT; CYTOKINES; ENDOTOXINS; FEMALE; FEVER; GENE EXPRESSION REGULATION; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LACTOFERRIN; MALE; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; SHIVERING; SIALOGLYCOPROTEINS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029796138     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 328:106, 1993
2. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771, 1993
3. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/ cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis 161:982, 1990
4. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Cerami A, Shires GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147, 1988
5. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162, 1988
6. Smith JW, II, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, Sznol M, Creekmore SP, Wells NF, Ruscetti FW, Keller JR, Hestdal K, Shimizu M, Rossio J, Alvord WG, Oppenheim JJ, Longo DL: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10:1141, 1992
7. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550, 1990
8. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA: A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 5:338, 1991
9. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kennedy JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551, 1992
10. Fisher CJ, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, for the Phase III rhIL-1ra Sepsis Syndrome Study Group: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1834, 1994
11. Mancilla J, Garcia P, Dinarello CA: The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 61:926, 1993
12. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB: Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 148:1486, 1992
13. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K, Grabstein KH, Dower SK: Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 90:6155, 1993
14. Sims JE, Giri JG, Dower SK: The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 72:9, 1994
15. Dower SK, Wignall JM, Schooley K, McMahan CJ, Jackson JL, Prickett KS, Lupton S, Cosman D, Sims JE: Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol 142:4314, 1989
16. Fanslow WC, Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK, Widmer MB: Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 248:739, 1990
17. Drevlow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM: Phase I study of recombinant human interleukin-1 receptor (RHUIL-1R) administered intra-articularly in active rheumatoid arthritis. Arthritis Rheum 36:S39, 1993
18. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK: Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol 146:2983, 1991
19. Mullarkey MF, Leiferman KM, Peters MS, Caro I, Roux ER, Hanna RK, Rubin AS, Jacobs CA: Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 152:2033, 1994
20. Martich GD, Boujoukos AJ, Suffredini AF: Response of man to endotoxin. Immunobiology 187:403, 1993
21. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280, 1989
22. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J Exp Med 173:1021, 1991
23. Nam MH, Reda D, Boujoukos AJ, Martich GD, Agosti J, Suffredini AF: Soluble recombinant human interleukin-1 receptor (rhIL-1R): Safety and pharmacokinetics in human volunteers. Clin Res 41:380A, 1993 (abstr)
24. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038, 1995
25. Scheffe H: The Analysis of Variance. New York, NY, Wiley, 1959
26. Nelson LS: Tables for testing ordered alternatives in an analysis of variance. Biometrika 64:335, 1977
27. Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 52:591, 1965
28. Snedecor GW, Cochrane WG: Statistical Methods. Ames, Iowa, Iowa State University, 1980
29. Fernandez-Botran R, Vitetta ES: Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med 174:673, 1991
30. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323, 1992
31. Rose-John S, Heinrich PC: Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 300:281, 1994
32. Davis S, Aldrich TH, Ip NY, Stahl N, Scherer S, Farruggella T, DiStefano PS, Curtis R, Panayotatos N, Gascan H: Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses. Science 259:1736, 1993
33. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021, 1992
34. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, Bird TA, Shanebeck K, Grabstein KH, Sims JE, Alderson MR: Elevated levels of shed type II IL-1 receptor in sepsis: Potential role for type II receptor in regulation of IL-1 responses. J Immunol 153:5802, 1994
35. Arend WP, Malyak M, Smith MF Jr, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of IL-1α, IL-1β, and IL-1 receptor antagonist soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 153:4766, 1994
36. Burger D, Chicheportiche R, Giri JG, Dayer JM: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 96:38, 1995
37. Dinarello CA: The interleukin-1 family: 10 years of discovery. FASEB J 8:1314, 1994
38. Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, Colotta F: The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179:739, 1994
39. Colotta F, Dower SK, Sims JE, Mantovani A: The type II "decoy" receptor: A novel regulatory pathway for interleukin 1. Immunol Today 15:562, 1994
40. Granowitz EV, Clark BD, Vannier E, Callahan MV, Dinarello CA: Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79:2356, 1992
41. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA: Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79:2364, 1992
42. Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW: Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2-induced cytokine production In vitro. J Immunol 152:3189, 1994
43. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo. Proc Natl Acad Sci USA 89:4835, 1992
44. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HSA, Stiles DM, Pribble J, Catalano M, Moldawer LL, Lowry SF: Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol 154:1499, 1995
45. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E, Shapiro L, Pribble JP, Stiles DM, Catalano MA, Wolff SM, Dinarello CA: Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 82:2985, 1993
46. Cannon JC, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79, 1990
47. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 338:1423, 1991
48. Van Deventer SJH, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520, 1990
49. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer ST, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
50. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF: The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896, 1990
51. Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S: Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxemia. J Infect Dis 163:89, 1991
52. Goldie AS, Fearon KHC, Ross JA, Barclay R, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC, for The Sepsis Intervention Group: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274:172, 1995
53. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K: Specific binding of interleukin 1 (IL-1)β and IL-1 receptor antagonist (IL-1ra) to human serum. High affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 5:427, 1993
54. Chensue SW, Bienkowski M, Eessalu TE, Warmington KS, Hershey SD, Lukacs NW, Kunkel SL: Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. J Immunol 151:3654, 1993
55. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F: Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94:449, 1994